Exhibit 99.1 Investor Contact: Lauren Morris 283-227-6409 l.morris@medpace.com FOR IMMEDIATE RELEASE Media Contact: Michael Maley 283-227-6367 m.maley@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2025 Results CINCINNATI, OHIO, October 22, 2025-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue for the three months ended September 30, 2025 increased 23.7% to $659.9 milli ...

Core Insights - Medpace Holdings, Inc. reported a revenue increase of 23.7% for Q3 2025, reaching $659.9 million compared to $533.3 million in Q3 2024 [1] - On a constant currency basis, revenue growth for Q3 2025 was 23.4% compared to the same period in the previous year [1] - The company's backlog as of September 30, 2025, indicates strong future revenue potential [1]

Company Overview - Medpace Holdings, Inc. is a global, full-service clinical research organization (CRO) that serves biotech, pharmaceutical, and medical device companies, known for its trusted execution and consistent delivery of results [2] - The company generates revenue through various services including clinical trial management, regulatory and medical affairs, laboratory and imaging services, and pharmacovigilance and data management [2] Business Model and Growth - Medpace focuses on mid-sized biotech and pharma clients, allowing it to differentiate through precise execution and a fully integrated, in-house service platform that ensures seamless delivery across all trial stages [3] - The company has a track record of consistent double-digit growth and strong margins, supported by operational efficiency and streamlined processes that minimize delays [3] - Medpace's holistic approach accelerates trial timelines, supports regulatory approvals, and helps bring innovative treatments to patients more quickly [4] Investment Thesis - The combination of high-quality execution, an integrated service offering, and a recurring demand model positions Medpace as a resilient and high-quality growth platform within the CRO industry, making it an attractive investment opportunity [4] - The stock has appreciated approximately 73% since a previous bullish thesis was published, indicating strong market performance and consistent growth [5] Market Position - Medpace is not among the 30 most popular stocks among hedge funds, with 42 hedge fund portfolios holding MEDP at the end of the second quarter, unchanged from the previous quarter [6]

Core Insights - The Giverny Capital Asset Management ("GCAM") model portfolio showed a net return of 6.79% for Q3 2025, underperforming the S&P 500 TR which returned 8.12% during the same period [2][4] - Significant declines in key holdings, particularly Constellation Software, which dropped 18% in September due to the sudden retirement of its CEO, Mark Leonard, impacted overall portfolio performance [4][5] - The investment landscape is characterized by a mix of economic uncertainty and stock market exuberance, with concerns about tariffs and the agricultural sector, yet enthusiasm for AI investments remains high [6][7] Performance Overview - The portfolio's year-to-date return stands at 12.57%, trailing the S&P 500's 14.83% [2] - Over the past three years, the portfolio has achieved an annualized return of 24.05%, while the S&P 500 has returned 24.94% [2] - The portfolio's largest holdings include Arista Networks, Alphabet, and Meta Platforms, which collectively represent a significant portion of the total assets [30] Key Holdings and Transactions - The portfolio initiated a 3.5% position in Taiwan Semiconductor (TSM), which is positioned as a leading manufacturer in the semiconductor industry, capitalizing on the growing demand for high-performance chips [19][21] - Medpace Holdings, a contract research organization, saw a substantial increase in stock value, rising over 50% in one day following a strong earnings report [11][12] - The portfolio has trimmed positions in several strong performers, including Alphabet and Meta, while fully exiting Credit Acceptance due to concerns over its competitive position [25] Market Context - The semiconductor industry is experiencing rapid advancements, with TSMC leading in manufacturing capabilities, particularly in producing chips at smaller nanometer specifications [20][22] - The market is currently focused on AI-related stocks, which have significantly contributed to S&P 500 returns since the launch of ChatGPT in November 2022 [13][14] - Concerns about geopolitical risks, particularly regarding Taiwan, are prevalent, as TSMC is a critical supplier for major tech companies [22][24] Investment Philosophy - The portfolio emphasizes investments in companies with founder involvement in management, which is believed to align interests and foster strong corporate cultures [8] - The management team expresses confidence in the quality of their holdings and the leadership of companies like Medpace and TSMC, despite broader market uncertainties [7][12] - The approach remains cautious regarding the sustainability of the current market rally, with a focus on long-term value creation rather than short-term speculation [7][26]

Company Performance - Medpace (MEDP) closed at $521.21, reflecting a +1.34% increase from the previous day, outperforming the S&P 500's decline of 0.63% [1] - Over the past month, Medpace shares have risen by 3.31%, surpassing the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92% [1] Upcoming Earnings - Medpace is set to release its earnings on October 22, 2025, with an expected EPS of $3.5, representing a 16.28% increase year-over-year [2] - The consensus estimate for revenue is $640.45 million, indicating a 20.09% growth compared to the same quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates project earnings of $14.03 per share and revenue of $2.46 billion, reflecting increases of +11.08% and +16.86% respectively from the previous year [3] Analyst Revisions - Recent changes to analyst estimates for Medpace indicate a favorable outlook on the company's business health and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests potential stock price performance [4] Valuation Metrics - Medpace has a Forward P/E ratio of 36.65, which is a premium compared to the industry average Forward P/E of 17.34 [5] - The PEG ratio for Medpace is currently 3.23, compared to the average PEG ratio of 1.73 for the Medical Services industry [6] Industry Ranking - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries [6][7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - Vulcan Value Partners reported positive absolute performance across all strategies in Q3 2025, with the All-Cap Composite leading at 5.5% net return [1] - Medpace Holdings, Inc. (NASDAQ:MEDP) was highlighted as a significant contributor to performance, with a one-month return of 2.47% and a 52-week gain of 50% [2][3] Performance Summary - Large Cap Composite returned 4.6% net of fees and expenses - Small Cap Composite returned 4.1% net - Focus Composite returned 3.7% net - Focus Plus Composite returned 3.7% net - All-Cap Composite returned 5.5% net [1] Medpace Holdings, Inc. Insights - Medpace reported strong Q2 results with revenue growth at a mid-teens rate and operating earnings up 20% year over year [3] - The company repurchased nearly 6% of outstanding shares during the quarter, enhancing its earnings outlook for the full year [3] - Positive trends such as a better biotech funding environment and faster client decision-making are expected to drive accelerated growth for Medpace [3] - The share price rose faster than the estimated value, leading to a strategic trimming of the position in the portfolio [3]

Core Insights - Headwaters Capital Management's third-quarter 2025 investor letter focused on AI and reported a portfolio return of -2.7% compared to a +5.3% gain for the Russell Mid Cap Index [1] Company Performance - Medpace Holdings, Inc. (NASDAQ:MEDP) was highlighted as a top contributor with a return of +64% in the quarter, driven by strong bookings despite a challenging biotech funding environment [3] - Medpace's stock closed at $527.40 on October 13, 2025, with a market capitalization of $14.816 billion, and it experienced a one-month return of 7.46% and a 49.28% increase over the last 52 weeks [2] - The company reported revenue of $603.3 million in the second quarter of 2025, marking a 14.2% year-over-year increase [4] Investment Strategy - Headwaters Capital Management noted that Medpace's disciplined capital allocation and market share gains make it a core long-term holding, despite the cyclical nature of its end markets [3] - The firm indicated that while Medpace has potential, certain AI stocks may offer greater upside potential with less downside risk [4]

Core Insights - Medpace (MEDP) is positioned to continue its earnings-beat streak, particularly in the upcoming earnings report, supported by a strong history of exceeding earnings estimates [1][5] - The company has an average surprise of 11.63% over the past two quarters, indicating consistent performance above expectations [1][5] Earnings Performance - For the most recent quarter, Medpace reported earnings of $3.1 per share, surpassing the expected $3 per share by 3.33% [2] - In the previous quarter, the company reported $3.67 per share against a consensus estimate of $3.06 per share, resulting in a surprise of 19.93% [2] Earnings Estimates and Predictions - Recent estimates for Medpace have been revised upward, with a positive Earnings ESP of +4.49%, suggesting increased analyst optimism regarding its near-term earnings potential [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a strong likelihood of another earnings beat in the upcoming report scheduled for October 22, 2025 [8] Statistical Insights - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions prior to earnings releases [7]

Group 1 - Medpace (MEDP) has returned 59.8% year-to-date, significantly outperforming the Medical sector, which has gained about 1.8% on average [4] - Medpace holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook with a consensus estimate for full-year earnings moving 10.4% higher in the past quarter [3] - The Medical Services industry, to which Medpace belongs, has lost an average of 0.3% so far this year, further highlighting Medpace's strong performance [5] Group 2 - Black Diamond (BDTX) is another Medical stock that has outperformed the sector with a year-to-date return of 86.5% and holds a Zacks Rank of 1 (Strong Buy) [4][5] - The Medical - Biomedical and Genetics industry, which includes Black Diamond, has gained 8.7% year-to-date and is currently ranked 96 [6] - Investors interested in Medical stocks should closely monitor both Medpace and Black Diamond for continued strong performance [6]

Core Insights - The article compares two Medical Services stocks, Solventum (SOLV) and Medpace (MEDP), to determine which offers better value for investors [1] Valuation Metrics - Solventum has a Zacks Rank of 1 (Strong Buy), indicating a stronger earnings outlook compared to Medpace, which has a Zacks Rank of 3 (Hold) [3] - SOLV's forward P/E ratio is 12.56, significantly lower than MEDP's forward P/E of 38.33, suggesting SOLV is more attractively priced [5] - The PEG ratio for SOLV is 3.03, while MEDP's PEG ratio is 3.37, indicating SOLV may offer better value relative to its expected earnings growth [5] - SOLV's P/B ratio is 3.54, compared to MEDP's P/B of 87.39, further highlighting SOLV's relative valuation advantage [6] - Based on these metrics, SOLV holds a Value grade of B, while MEDP has a Value grade of D, indicating a stronger value proposition for SOLV [6] Earnings Outlook - SOLV is noted for its improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, positioning it as the superior value option at present [7]